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Background: Allopurinol is a frequently prescribed drug. In inflammatory bowel disease patients who shunt
thiopurine metabolism towards more toxic and less desirable pathways, allopurinol is proving to be an effective
add on therapy with good resultant disease control and less treatment side effects. As many such patients are
young, the potential for pregnant women to be exposed to allopurinol is increasing. The safety of allopurinol in
pregnancy is not known however.
Case presentation: We report three cases of safe use of allopurinol in pregnancy for women with inflammatory
bowel disease. This included 2 patients with ulcerative colitis and 1 patient with fistulising Crohn’s disease.
Allopurinol was used throughout pregnancy in all patients. All 3 pregnancies resulted in normal healthy babies
born at term by Caesarean section.
Conclusion: It is important to evaluate and document the safety of allopurinol during pregnancy, as it is finding
new roles in young patients. These three cases add significantly to the very limited data on allopurinol use in
pregnancy. We encourage reporting of all cases of allopurinol use in pregnant patients and suggest an allopurinol
pregnancy registry to document drug exposures and outcomes.
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Allopurinol was discovered by Gertrude Elion in the late
1950’s in studies intended to improve thiopurine efficacy
[1]. Since registration by the FDA in 1966 it has been
predominantly used to treat patients with hyperuricae-
mia. Most such patients are either male, beyond child-
bearing years or undergoing chemotherapy, and hence
potential teratogenicity of allopurinol has not been a
concern. However, allopurinol is increasingly prescribed
to younger female patients and there is minimal infor-
mation on allopurinol safety in pregnancy.
There are several reasons for the increasing prescrip-
tion of allopurinol to younger female patients. With in-
creasing obesity gout is increasingly seen in women of
child-bearing age. Leukaemia is a common malignancy* Correspondence: Muhmmad.Fazal@health.sa.gov.au
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reproduction in any medium, provided the orin the young and chemotherapy induced hyperuricemia
is treated with allopurinol. Furthermore, allopurinol use
is expanding beyond hyperuricaemia to combination use
with thiopurines (6-mercaptopurine or azathioprine) in
some cases of inflammatory bowel disease (IBD) and
autoimmune hepatitis.. Allopurinol is used in this situ-
ation to promote the metabolism of azathioprine/6-
mercaptopurine along therapeutically favourable pathways
in cases where preferential production of 6 methyl mercap-
topurine (6MMP) rather than 6 thioguanine nucleotides
(6TGN) has lead to treatment failure or toxicity [2-4].
Since these patients are frequently young and female, this
indication has also expanded the use of allopurinol in po-
tentially fertile women.
Allopurinol is categorised pregnancy risk “C” by the
FDA as it inhibits purine synthesis and hence may have
direct affects on dividing cells in utero. It is excreted in
breast milk and caution is advised when used in nursing
mothers. Animal studies with allopurinol have shownd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Fazal et al. BMC Gastroenterology 2013, 13:172 Page 2 of 5
http://www.biomedcentral.com/1471-230X/13/172variable results. One study in 1972 reported cleft palate
and skeletal abnormalities in mice embryos exposed
to large doses of allopurinol [5]. However, studies in
other animal species report no foetal harm [6]. Pub-
lished human data are scarce but growing. Just recently
Hoeltzenbein et al. have reported case series of 31 pro-
spectively determined pregnancies with 1st trimester
allopurinol exposure. The rate of major malformations
was in the expected range, however one infant had severe
malformations including microphthalmia, cleft lip and
palate, renal hypoplasia, low-set ears, hearing deficit,
bilateral cryptorchidism, and micropenis [7]. This pheno-
type is of possible concern as it resembles another
reported case of multiple congenital anomalies in an allo-
purinol exposed infant [8]. These reports have raised con-
cerns regarding potential teratogenicity of allopurinol.
However safe use of allopurinol and mercaptopurine in a
pregnant ulcerative colitis patient has been reported with
a resultant favourable pregnancy outcome [9]. There are
also four cases reported of allopurinol use in pregnant
women with leukaemia. Two of these pregnancies resulted
in normal healthy infants and two in adverse outcomes
(intrauterine growth retardation and intrauterine foetal
death), both of which were attributable to other causes
[10-12]. In these cases allopurinol was used in the 2nd or
3rd trimester only.
Although it is likely that there have been exposures to
allopurinol in multiple pregnancies, very few have been
reported as mentioned above. We report the safe use of




A 29 year old woman diagnosed with ulcerative colitis in
July 2007 had several hospital admissions over the fol-
lowing 18 months requiring IV steroids and cyclosporine
for acute ulcerative colitis despite good reported compli-
ance with mesalazine and azathioprine. In 2009 thiopur-
ine metabolites were assessed (newly available) and she
was documented to have a low 6TGN and a 6MMP:6TGN
ratio of 51 consistent with MMP preferential shunting. She
was commenced on allopurinol 100 mg PO daily and the
dose of azathioprine reduced to 50 mg PO daily. Subse-
quently she was weaned off steroids and cyclosporine,
remaining clinically stable on allopurinol and azathio-
prine. One year after addition of allopurinol in 2010,
her 6MMP:6TGN ratio was 0.25.
In 2011 she conceived her first child and at about
10 weeks gestation had a flare of ulcerative colitis requiring
admission. On arrival, it was apparent that she had a co-
lonic perforation secondary to severe ulcerative colitis. An
urgent subtotal colectomy with end ileostomy was per-
formed. First trimester ultrasound revealed a healthy foetusat expected gestational age. She was maintained on allo-
purinol 100 mg and azathioprine 75 mg PO daily postoper-
atively due to concerns about disease control in the long
rectal stump. At the time it was considered that the major-
ity of the risk of teratogenic effects of allopurinol had
already occurred, and that the potential benefit in control-
ling disease for the remainder of the pregnancy outweighed
the potential harm of ongoing drug exposure. She was dis-
charged 20 days later after good clinical recovery.
Her pregnancy progressed unremarkably. She under-
went an emergency Caesarean section at 37 weeks gesta-
tion following spontaneous rupture of membranes. She
delivered a healthy 3 kg baby boy. He had an inguinal
hernia repair at 5 weeks and remains well since then.
Case 2
A 29 year old woman was referred with steroid dependent
ulcerative colitis diagnosed 2 years earlier. She was treated
with prednisolone 40 mg PO daily, azathioprine 150 mg
PO daily, mesalazine tablets 2 g PO twice daily and mesala-
zine foam enemas 4 g PR daily. She was also taking folate
0.5 mg PO daily as she was attempting to conceive. Her
TPMT (thiopurine methyltransferase) activity before ther-
apy was normal at 8.5U/mL (7.0 – 14.5). In evaluating her
steroid dependency her 6TGN was found to be 134 with
6MMP 5560, giving a 6MMP:6TGN ratio of 41, consistent
with shunting. It was judged that an increased azathioprine
dose would have lead to a large 6MMP rise (with such a
ratio) and probable toxicity, so co-therapy was decided on.
The azathioprine dose was reduced to 25 mg PO daily and
allopurinol 100 mg PO daily was dosed concomitantly. She
declined treatment with a biological agent or entry into a
clinical drug trial as she was attempting to conceive.
She conceived 15 months later on the allopurinol &
azathioprine co-therapy. The prednisolone dose was re-
duced to 7.5 mg PO daily; the lowest dose she had been
on. To avoid a flare during pregnancy the decision was
to maintain her at low dose prednisolone. At the time,
her 6TGN was 254 and 6MMP was < 500 (6MMP:6TGN
ratio ~2). Allopurinol, azathioprine and prednisolone
were continued for the duration of the pregnancy and
her ulcerative colitis was well controlled.
A healthy baby boy was delivered by caesarean section at
term due to breech position. She elected not to breast feed
for personal reasons. Sixteen months after delivery of her
first child she suffered a miscarriage at 6.5 weeks preg-
nancy. Foetal chromosomal studies were not performed.
She plans to fall pregnant again in the following year before
entering a clinical trial to manage her ulcerative colitis. She
continues on combination azathioprine and allopurinol.
Case 3
A 28 year old woman presented in year 2000 with an
ischiorectal abscess at age 17. This was drained after
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a cable tie seton before resolving. She re-presented in
2002 with obstructive symptoms and a small bowel
series revealed stenosing ileocaecal Crohn’s disease.
From 2002 and 2008 she was managed with azathioprine
150 mg PO daily with intermittent steroid courses and
one induction dose of infliximab (prior to funded access
to therapy).
In June 2008, she was commenced on induction and
maintenance therapy with adalimumab for recurrent
perineal fistulae, remaining on concomitant azathioprine
150 mg PO daily. In Feb 2009, she ceased azathioprine
as she was in clinical remission. However in June 2009, a
flare requiring a course of prednisolone occurred and
azathioprine 150 mg PO daily was recommenced. Pred-
nisolone was ceased, but she remained mildly symptom-
atic. Metabolite testing at this time revealed a 6TGN of
181 and a 6MMP of 4558 (6MMP:6TGN ratio of 25). Her
dose was gradually increased to azathioprine 225 mg PO
daily, however, repeat testing revealed 6 TGN 253 and 6
MMP 8093; a ratio of 32, consistent with shunting. Whilst
liver function tests, iron and inflammatory markers were
all normal, the patient complained of lethargy and nausea.
She was placed on concomitant allopurinol 100 mg PO
daily and the azathioprine dose was reduced to 50 mg PO
daily, together with continued adalimumab. A repeat me-
tabolite testing revealed 6TGN of 493 and 6MMP of < 250
with resolution of nausea and lethargy. In March 2011 she
reported feeling the best she had ever felt. She subse-
quently conceived in October 2011. She decided to cease
adalimumab at that stage, but remained on azathioprine
and allopurinol throughout her pregnancy with no further
flares. She delivered a healthy baby boy by elective caesar-
ean section at 38 weeks, and has remained in clinical
remission on last review in September 2012.
Conclusion
Despite 50 years of clinical use there are very scant data
to date regarding the use of allopurinol in pregnancy.
Notably allopurinol has found new applications particu-
larly in combination with thiopurines. The use of allo-
purinol in conjunction with thiopurines was reported in
cadaveric renal transplants with favourable outcome in
terms of reduced rejection episodes [13]. It is now also
being used in this fashion in an increasing number of
IBD patients i.e. those with preferential production of
6MMP over 6TGN [2,3]. These patients are referred
to as “shunters” [4] and co-treatment with allopurinol
(pioneered recently in the management of IBD) decreases
6-MMP and increases 6-TGN concentrations to achieve
“therapeutic” concentrations of 6TGN; hence a greater
chance of effective disease control [14,15]. When used as
co-therapy in this setting, allopurinol is continued long
term to maintain a desirable profile of 6MMP:6TGN.These patients are often young and female; consequently
allopurinol is now being prescribed to a greater number of
potentially fertile IBD women as a long-term therapy. The
inhibition of purine metabolism by allopurinol raises con-
cerns of teratogenicity, but as yet there appear to be only 2
cases with adverse pregnancy outcomes possibly related to
allopurinol [7,8] albeit with uncertain causality.
Women with IBD have an increased risk of adverse
pregnancy outcomes (odds ratio, 1.65; 95% confidence
interval, 1.09-2.48) [16,17]. The main adverse outcomes
are of impaired foetal growth and difficulties with main-
tenance of pregnancy, with a greater incidence of prema-
ture births and low birth weight infants reported in
women with IBD [16]. However, the activity of IBD dur-
ing pregnancy appears to be the most important deter-
minant of these adverse outcomes rather than drug
therapy to control IBD; moreover activity of IBD during
pregnancy is predominantly determined by the activity of
disease at conception [18]. Hence most authors emphasize
the importance of optimal disease control pre-conception,
and continuing necessary medication during pregnancy.
Therapeutic options can be limited for IBD patients, as
many do not maintain remission on a 5-aminosalicylates,
and long-term steroid therapy is not acceptable due to cu-
mulative toxicity and frequent lack of mucosal healing.
Anti-TNF therapy (anti-tumour necrosis factor) does not
always succeed and for many patients there are contrain-
dications to these agents. In addition, in some jurisdictions
anti-TNF drugs are not widely available due to funding
constraints. In ulcerative colitis surgery is “curative”, yet it
is not desired by most young patients, and surgery has its
own morbidity and longer term effects. Thiopurines are
pregnancy category D and their use has been associated
with preterm birth (perhaps as a marker of worse disease)
but not with low birth weight or congenital abnormalities
[19], and they are therefore widely regarded as the treat-
ment of choice in pregnant patients with IBD that is diffi-
cult to control with 5-aminosalicylates [20,21]. Whilst
Jharap B et al. have recently reported some concerns in in-
fants born to IBD mothers on thiopurines [22], these data
do not appear to have translated into a significant clinical
problem for IBD mothers and babies, and allopurinol ther-
apy should not add to the observed anaemias in infants
unless higher than recommended 6TGNs are allowed.
With the rise in IBD and the increasing use of con-
comitant allopurinol with thiopurine treatment, the use
of allopurinol in women of child-bearing potential is
growing. For example of ~800 IBD patients at the Royal
Adelaide Hospital, ~50% are on thiopurines and 15%
of thiopurine users have been identified as “shunters”.
Nearly 50% of these shunters are women younger than
50. Given the understandable reticence of doctors and
potential parents to expose infants to possibly dangerous
drugs, good clinical and experimental data to better
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These three cases add significantly to the very limited
data on allopurinol use in pregnancy in general and in
pregnant IBD patients on thiopurines in particular. The
largest case series to date examining allopurinol safety in
pregnancy by Hoeltzenbein et al. cited earlier, provides
both reassurance (in that the absolute rate of congenital
abnormalities was only as expected) and concern (with
the affected infant having a constellation of abnormalities
similar to another reported allopurinol-exposed case).
One should be aware however that none of the cases in
the German series were patients with IBD, and all of the
women were multiply medicated and with major comor-
bidities. Moreover, there is likely to be a bias as they all
resulted from referrals to a clinical teratology and drug
risk assessment clinic. As our cases only came to light
post delivery in the 1st case, when one author (JMA)
questioned colleagues, thus leading to the discovery of
the other cases, we believe it is likely that many other
cases with good outcomes are currently un-reported.
Thus, until a greater number of exposed pregnancies are
reported, it is uncertain what the real rate and scope of
any danger is.
In response to a question at Digestive Diseases
Week 2012 during a session on drugs in pregnancy,
invited speakers and a large audience were unable to
make any particular comment on allopurinol experi-
ence and outcomes in this setting (JM Andrews per-
sonal communication). For many newer drugs there are
registries collecting data on drug exposure during preg-
nancy and outcomes. However, there is a lack of similar
initiatives for older drugs with sparse safety data, like
allopurinol. Therefore we encourage the reporting of all
cases of allopurinol use in pregnancy and the resultant
outcomes in the exposed infants. No pregnancy is risk
free – even without a chronic disease or drug therapy;
however pregnancy is an emotional charged issue. There-
fore we would recommend that pre-pregnancy counse-
lling of all IBD patients takes place, addressing both risks
of therapy and of active disease, and that patients and
their treating team make decisions in a collaborative
fashion with the best currently available information. As
treatments evolve, prospective follow-up of offspring
from IBD-pregnancies should be resourced.
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